Business Context and Reporting Period
This Form 6-K filing by AMBEV S.A. covers the period from July 1, 2022, to July 31, 2022. The report was filed on August 8, 2022. The document serves as a consolidated report of transactions in securities and derivatives by the Company's Board of Directors, Management, and Fiscal Council, in compliance with Article 11 of CVM Instruction # 358/2002.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly limited to the disclosure of insider trading activity and does not contain financial performance data.
Material Changes
There were no material changes in the securities holdings of the reported groups during the month of July 2022. The filing explicitly states that the only transactions presented were those in compliance with the regulation, and the data tables show no activity.
- Board of Directors: Initial balance of 12,194,947 Common Shares and 0 ADRs. Final balance remained unchanged with no transactions recorded.
- Management: Initial balance of 2,328,292 Common Shares and 541,613 ADRs. Final balance remained unchanged with no transactions recorded.
- Fiscal Council: Initial balance of 0 Common Shares. Final balance remained unchanged with no transactions recorded.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or operational commentary.
Important Facts for Investors
- No insider transactions (purchases or sales) occurred for the Board of Directors, Management, or Fiscal Council during July 2022.
- The filing confirms compliance with Brazilian securities regulations (CVM Instruction # 358/2002) regarding the disclosure of related person transactions.
- Investors should refer to the company's Form 20-F or quarterly earnings releases for financial performance metrics, as this Form 6-K contains only transactional data.